Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 4, 2017
| Ohr Pharmaceutical, Inc. |
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 333-88480 | 46-5622433 | ||
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer | ||
| of Incorporation) | File Number) | Identification No.) |
| 800 Third Avenue, 11th Floor, New York, NY | 10022 |
| (Address of Principal Executive Offices) | (Zip Code) |
| (212) 682-8452 |
| (Registrant’s Telephone Number, Including Area Code) |
| Not Applicable |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01 | Other Events. |
On April 4, 2017, Ohr Pharmaceutical, Inc. issued a press release announcing that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits: |
| 4.1 | Form of Warrant |
| 10.1 | Form of Securities Purchase Agreement |
| 99.1 | Press Release dated April 4, 2017 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OHR PHARMACEUTICAL, INC. | ||
| (Registrant) | ||
| Date: April 4, 2017 | By: | /s/ Sam Backenroth |
| Sam Backenroth | ||
| Chief Financial Officer | ||
| EXHIBIT INDEX | |||
| Exhibit No. | Description | ||
| 4.1 | Form of Warrant | ||
| 10.1 | Form of Securities Purchase Agreement | ||
| 99.1 | Press Release dated April 4, 2017 | ||